| Old Articles: <Older 6381-6390 Newer> |
|---|
 |
The Motley Fool
June 10, 2010
Denise Gellene |
Syndax's Breast Cancer Drug Advances, and More San Diego Life-Sciences News The pace of life-sciences news slowed in the past week, but we know from experience that the lull is temporary.   |
The Motley Fool
June 9, 2010
Brian Orelli |
The Drug Passed, but the Stock Fell? Regeneron only bats .500. |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
The Motley Fool
June 9, 2010
Denise Gellene |
Gen-Probe Prostate Cancer Test Looks Promising The new test could eliminate need for painful biopsies. |
The Motley Fool
June 8, 2010
Brian Orelli |
Injecting Uncertainty Into the Multiple Sclerosis Market Novartis' oral MS drug could be a blockbuster -- if it can get past the FDA. |
The Motley Fool
June 8, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Is Celgene the new Genentech? Maybe not -- but it's cheap. |
The Motley Fool
June 8, 2010
Jim Mueller |
Johnson & Johnson: Strengths, Weaknesses, Opportunities, Threats A quick look inside this business of Band-Aids and drugs. |
The Motley Fool
June 8, 2010
Ryan McBride |
Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks. |
The Motley Fool
June 7, 2010
Brian Orelli |
Bristol Investors Go Crazy Wild. Are They Justified? Bristol-Myers Squibb is up a lot on an upgrade and some positive data coming out of the American Society of Clinical Oncology meeting, but investors need to be careful. |
The Motley Fool
June 7, 2010
Erin Kutz |
Biotech Roundup: Glaxo's SR One, Covidien, Follica The latest biotech news includes new funding. |
| <Older 6381-6390 Newer> Return to current articles. |
